1. Home
  2. |Insights
  3. |Travel Expense Rebates And Incentives Result In $40 Million FCA Settlement

Travel Expense Rebates And Incentives Result In $40 Million FCA Settlement

Client Alert | less than 1 min read | 07.29.05

PricewaterhouseCoopers has agreed to pay $41.9 million to settle a qui tam civil False Claims Act lawsuit brought by a former partner alleging that the accounting firm had knowingly overbilled various government agencies for travel in conjunction with auditing and consulting work by failing to give the government credit for commissions, rebates, and incentives that travel companies and credit card issuers extended to the firm. The former partner turned whistleblower, who alleged that the accounting firm's management ignored internal complaints about the practice, reportedly is expected to receive between 15 and 25 percent of the government's $41.9 million recovery, plus $1.6 million in legal fees and costs.

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...